nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2004 | Letter to the Editor

Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals

verfasst von: H. Palmedo, J. Bucerius

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2004

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Valdés Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 2004;31:929–31.

McCready VR, O’Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging 2002;29(10):1271–5.CrossRefPubMed

Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991;27(9):1084–6.CrossRefPubMed

Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21(15):2869–75.CrossRefPubMed

Titel: Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals
verfasst von: H. Palmedo
J. Bucerius
Publikationsdatum: 01.11.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1665-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2004

Clinical feasibility of two-step streptavidin/111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis

Incremental predictive value of myocardial scintigraphy with 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary intervention

Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma

Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases

Small animal PET: aspects of performance assessment

A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia